Detrás de los titulares sobre el cáncer

Actualización: Inmunoterapia con dostarlimab obtiene aprobación de la FDA para tratar el cáncer de endometrio recurrente o avanzado

The FDA has given accelerated approval for the immunotherapy agent dostarlimab (Jemperli) to treat recurrent and advanced endometrial cancer that has a biomarker called mismatch repair deficiency (dMMR). This adds a new treatment option for people with recurrent or advanced endometrial cancer. (posted 5/18/21)

Este artículo está disponible en español.

Estudio: El consumo diario de una alta dosis de aspirina durante al menos dos años disminuye el riesgo de padecer cáncer colorrectal pero no otros tipos de cáncer en personas con síndrome de Lynch

Research has shown that daily aspirin use can reduce the risk of colon and other cancers. The Cancer Prevention Program 2 (CaPP2) study looked at the effect of daily aspirin in patients with Lynch syndrome. After 10 years of follow-up, the results showed that taking daily aspirin for two years reduced the frequency of colon cancer in patients with Lynch syndrome, and importantly, did not result in an increase in side-effects or complications. No benefit was seen for other Lynch syndrome-related cancers, including endometrial cancer. (5/17/21)

Este artículo está disponible en español.

Estudio: Forma en la que el índice de masa corporal (IMC) puede afectar el efecto favorable del consumo de aspirina en la protección contra el cáncer colorrectal y de ovario

This study looked at the impact of daily aspirin use on the risk for many types of cancers and whether this effect can be modified by risk factors such as obesity, smoking, physical inactivity or a family history of cancer. Daily aspirin use: 

• lowered the risk for colorectal cancer, but this effect was lost as Body Mass Index (BMI) increased.
• lowered the risk of ovarian cancer risk among obese women.
• offered little or no protection against breast, endometrial or advanced prostate cancer.

(posted 3/19/21)

Este artículo está disponible en español.